Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $53.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price boosted by Wedbush from $50.00 to $53.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price target on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $55.29.

Kiniksa Pharmaceuticals International Trading Up 2.3%

Shares of NASDAQ KNSA opened at $44.49 on Wednesday. Kiniksa Pharmaceuticals International has a 12-month low of $18.25 and a 12-month high of $49.12. The stock has a 50 day simple moving average of $42.96 and a 200-day simple moving average of $39.77. The company has a market cap of $3.37 billion, a PE ratio of 60.12 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company’s revenue for the quarter was up 65.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) EPS. Sell-side analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the sale, the chief operating officer owned 16,666 shares of the company’s stock, valued at $692,638.96. The trade was a 41.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the sale, the chief financial officer owned 12,086 shares in the company, valued at $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 123,623 shares of company stock valued at $5,236,389. 53.48% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC increased its position in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after purchasing an additional 250 shares in the last quarter. Mariner LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 2.0% during the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after buying an additional 266 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 2.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock worth $678,000 after buying an additional 406 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Kiniksa Pharmaceuticals International by 7.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.